Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster

Rev Inst Med Trop Sao Paulo. 2022 Jun 17:64:e43. doi: 10.1590/S1678-9946202264043. eCollection 2022.

Authors

Almir Ribeiro da Silva Jr^{1

2}, Lucy Santos Villas-Boas², Anderson Vicente de Paula², Tania Regina Tozetto-Mendoza², Layla Honorato², Steven S Witkin^{1

2

3}, Maria Cassia Mendes-Correa^{1

2}

Affiliations

¹ Universidade de São Paulo, Faculdade de Medicina, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil.
² Universidade de São Paulo, Faculdade de Medicina, Instituto de Medicina Tropical de São Paulo, Laboratório de Investigação Médica em Virologia (LIM-52), São Paulo, São Paulo, Brazil.
³ Weill Cornel Medicine, Department of Obstetrics and Gynecology, New York, New York, USA.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Neutralizing*
Antibodies, Viral
COVID-19* / prevention & control
Humans
SARS-CoV-2
Vaccination
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Neutralizing
Antibodies, Viral
Vaccines, Synthetic
mRNA Vaccines

Supplementary concepts

SARS-CoV-2 variants